Deerland Enzymes, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Deerland Enzymes, Inc. - overview
Established
1990
Location
Kennesaw, GA, US
Primary Industry
Food
About
Deerland Enzymes, Inc. specializes in advanced microbiome solutions, providing a diverse range of probiotics, prebiotics, postbiotics, enzymes, and bacteriophage technologies to support health and wellness across various sectors globally. Founded in 1990 and headquartered in Kennesaw, US, Deerland Enzymes, Inc. focuses on microbiome-related health solutions.
The company has undergone a pivot in its operations with its recent acquisition by Archer Daniels Midland in November 2021, a strategic move aimed at enhancing the growth of dietary supplements. Scott Ravech serves as CEO, leading the company's vision in the health and wellness sector. The company offers a comprehensive portfolio of products designed to meet the increasing demand for health and wellness, including probiotics, prebiotics, postbiotics, enzymes, and bacteriophage technology. These offerings support various health aspects like digestive health, immune function, weight management, and skin health.
Deerland caters to a diverse clientele, including brands in functional foods, beverages, dietary supplements, and animal nutrition, marketing its products globally with a significant presence in North America, Europe, and parts of Asia. Deerland Enzymes, Inc. generates revenue through direct business transactions and partnerships with clients in the health and wellness sector. This includes sales of flagship products such as branded probiotics, prebiotics, and enzymes to manufacturers and retailers.
Their pricing aligns with industry standards for functional ingredients, with clients purchasing in bulk to incorporate these solutions into consumer products. With the acquisition by Archer Daniels Midland finalized in November 2021, Deerland Enzymes, Inc. aims to bolster its new product development strategies and expand into new markets. The focus includes enhancing its product offerings and leveraging Archer Daniels Midland’s resources to penetrate additional global markets, particularly in regions experiencing growth in microbiome health awareness.
The strategic rationale behind this acquisition is to empower growth in dietary supplements and functional foods, ultimately enhancing service delivery to customers worldwide.
Primary Industry
Food
Sub Industries
Education & Training Services, Education & Training Website, Health Foods & Nutritional Supplements
Website
www.deerland.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Deerland Enzymes, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Deerland Enzymes, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | National Enzyme Company, Inc. | - | ||||||||
| Growth | Completed | Deerland Enzymes, Inc. | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.